Zelluna to Present Early Clinical Data for TCR-NK Therapy Platform
Event summary
- Zelluna will host a Capital Markets Update on April 14, 2026, in Oslo to discuss progress on its TCR-NK off-the-shelf cell therapy platform.
- Presentations will be given by CEO Dr. Namir Hassan and Professor Fiona Thistlethwaite, lead principal investigator for the ZIMA-101 study.
- Initial clinical data for Zelluna’s lead candidate, ZI-MA4-1, is expected from mid-2026 following its Clinical Trial Application submission to the UK MHRA in December 2025.
The big picture
Zelluna’s Capital Markets Update comes at a critical juncture as the company prepares to release initial clinical data for its lead candidate, ZI-MA4-1. The event underscores the growing interest in TCR-NK therapies for solid cancers, a segment that has seen significant investment and innovation. The company’s ability to deliver promising early data could position it as a key player in the rapidly evolving cell therapy landscape.
What we're watching
- Clinical Data Impact
- How early clinical data for ZI-MA4-1 will influence investor sentiment and strategic partnerships.
- Regulatory Progress
- The pace at which Zelluna advances its clinical trials following MHRA approval.
- Market Positioning
- Whether Zelluna can differentiate itself in the competitive TCR-NK therapy space.
Related topics